[89Zr]Zr-PSMA-617

[89Zr]Zr-PSMA-617 is an investigational radiopharmaceutical diagnostic agent used for positron emission tomography (PET) imaging of prostate cancer. It consists of the small-molecule ligand PSMA-617, which has high affinity for the extracellular domain of the prostate-specific membrane antigen (PSMA) overexpressed on prostate cancer cells, chelated with the positron-emitting radioisotope zirconium-89 ($^{89}$Zr). Due to the relatively long physical half-life of $^{89}$Zr (approximately 78.4 hours), this tracer allows for delayed imaging time points (e.g., 24 to 72 hours post-injection). This extended imaging window can enhance the tumor-to-background ratio and improve the detection of low-volume biochemical recurrence compared to standard tracers with shorter half-lives, such as $^{68}$Ga-PSMA-11 or $^{18}$F-DCFPyL. It is primarily utilized in clinical research for the localization of prostate cancer recurrence and for pre-therapeutic dosimetry planning in patients undergoing PSMA-targeted radioligand therapy.

Other names

89Zr-labeled PSMA-617Zirconium-89 PSMA-617Zirconium89 PSMA-617Zirconium 89 PSMA-61789Zr-PSMA-617 PET/CT